Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0096

Scientific exchange · Dr. Liam Quinn

11 Aug 2026 · Phone · Dr. Liam Quinn, Royal Marsden · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0096MI request

Capture insight from this engagement

Location: Vall d'Hebron
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Brain-metastasis subgroup data

Scientific content used

irAE management guide
VTX core scientific deck v3.2

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Scientific exchange with radiation oncologist at Vall d'Hebron. Discussed brain-metastasis subgroup data.

Insights captured (1)

Capture insight

INS-0003Medium
Brain-metastasis subgroup data
Brain-metastasis subgroup data: request for data reported by thoracic medical oncologist (GB).
Routed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 2
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0096

Audit history (0)

All create, update and approval events for this record

No audit events in sample data